White House Unveils TrumpRx Portal Aiming to Cut Prescription Costs

President Donald Trump on Thursday, Feb. 5, 2026, introduced TrumpRx, an online platform designed to steer U.S. consumers toward lower-priced prescription medicines. The site is a cornerstone of the administration’s ongoing push to narrow the gap between domestic drug costs and those paid in other industrialized nations.

How the Platform Works

TrumpRx does not operate as a virtual pharmacy. Instead, it serves as a centralized gateway that redirects users to pharmaceutical companies’ own direct-to-consumer portals or provides printable coupons for use at retail pharmacies. Patients willing to pay cash and bypass traditional insurance billing are the primary target audience, according to a White House fact sheet.

Visitors who click on a specific product are routed to the manufacturer’s ordering system. For instance, selecting the weight-loss injection Zepbound transports users to LillyDirect, an Eli Lilly site that processes prescriptions, handles payment and arranges delivery.

Initial Industry Participants

Five drugmakers—AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk and Pfizer—have products displayed at launch. The administration said agreements with at least 14 additional companies have been reached, and their medicines will be added “in the coming months.” Participating firms voluntarily set cash prices for select brand-name therapies, positioning those amounts as substantial markdowns from published list prices.

Sample Prices Promoted at Launch

The portal highlights several high-demand products, particularly GLP-1 medications used for diabetes and obesity management:

• Ozempic (Novo Nordisk) diabetes injection: starting at $199 per month, compared with a list price near $1,000.
• Wegovy (Novo Nordisk) obesity injection: starting at $199 per month, down from roughly $1,350.
• Wegovy oral formulation: introductory doses listed at $149 per month.
• Zepbound (Eli Lilly) obesity injection: starting at $299 per month, versus an approximate $1,086 list price.
• Gonal-F (EMD Serono) fertility injection: advertised at $168, with no list comparator provided.

Dozens of additional therapies—including treatments produced by Amgen, Merck, Gilead and Bristol Myers Squibb—are expected but were not yet visible on Thursday evening.

Policy Context

The TrumpRx initiative complements the administration’s broader “most favored nation” strategy, which seeks to align U.S. drug prices with the lowest levels paid abroad. Domestic prescription costs currently average two to three times those in other developed economies and can be as much as ten times higher, according to Rand Corporation research.

Under voluntary arrangements negotiated with the White House, participating manufacturers also committed to offer Medicaid programs discounted rates on certain medicines. The administration characterizes these deals as landmarks intended to create downward pressure across the drug-pricing landscape.

Potential Savings—and Limitations

Health policy analysts caution that the real-world benefit for many insured patients remains uncertain. Insurance plans, pharmacy benefit managers (PBMs) and government programs routinely secure rebates and confidential concessions that shrink the effective price of brand-name drugs. A Congressional Budget Office study places average Medicaid discounts above 75 percent of list prices, while separate research shows typical Medicare Part D discounts near 40 percent.

Imagem: financial planning 7

Because TrumpRx prices are compared with undiscounted list figures, an individual’s out-of-pocket expense through insurance could equal or undercut the cash price advertised on the portal. Moreover, medications purchased outside an insurance benefit may not count toward a deductible or annual out-of-pocket maximum, reducing the financial advantage for policyholders.

Still, supporters argue that the portal could expand access for people lacking comprehensive coverage or seeking drugs that employers or insurers decline to reimburse. Weight-loss therapies, for example, have faced limited insurance uptake despite rising demand. Medicare coverage for such treatments is scheduled to begin later this year under the agreements with Eli Lilly and Novo Nordisk, but many commercial plans remain hesitant.

Industry Reaction

Several pharmaceutical executives have indicated conditional support for direct-to-consumer channels. Bristol Myers Squibb, which offers a cash-price option for its blood thinner Eliquis, plans to link its own purchasing site to TrumpRx after additional internal review. The company has signaled interest in expanding the model to more products where it “makes business sense.”

Eli Lilly has described itself as an early adopter of cash-pay programs and views the federal platform as a mechanism to replicate that approach across the sector.

Next Steps

The administration intends to add more discounted therapies and participating manufacturers over time. Officials did not specify exact timelines but indicated that additional listings would appear as agreements are finalized and technical integrations completed.

Analysts will be monitoring consumer uptake, comparative pricing trends and the portal’s impact on existing insurance dynamics. For now, TrumpRx presents an alternative purchasing route for U.S. patients prepared to evaluate whether a cash transaction delivers meaningful savings on their specific prescriptions.

Crédito da imagem: Aaron Schwartz / Bloomberg / Getty Images